Symrise enhances its health and wellness portfolio through the acquisition of Probi, focusing on innovative solutions for human and pet health.

Target Information

Symrise, a global leader in the flavor and nutrition industry, is strategically enhancing its portfolio by integrating Probi, a renowned provider of clinically proven biotic solutions. This acquisition is set to strengthen Symrise's commitment to health and wellness, particularly in the sectors of human and pet health. The announcement coincides with Symrise's participation at Vitafoods Europe 2025, where it will showcase innovative health solutions focused on healthy aging, joint health, and urinary health.

Symrise aims to deliver science-backed, nature-sourced health active solutions that address both consumer needs and industry trends. By incorporating Probi's expertise, Symrise can enhance its offerings with clinically validated biotic solutions.

Industry Overview

The health and wellness industry is witnessing significant growth globally, driven by an increasing consumer awareness of the importance of nutrition in overall healt

View Source

Similar Deals

Sandoz AG Just – Evotec Biologics EU

2025

Merger Bio Therapeutic Drugs Germany
BioNTech CureVac

2025

Merger Bio Therapeutic Drugs Germany
Smart Reporting Fluency for Imaging

2025

Merger Medical & Diagnostic Laboratories Germany
Sanner GmbH Springboard Pro Ltd

2024

Merger Advanced Medical Equipment & Technology (NEC) Germany
Hitachi Ltd. MA micro automation GmbH

2024

Merger Drug Delivery Systems Germany

Symrise

invested in

Probi

in 2025

in a Merger deal

Deal Parameters
Industry
Country
Seller type

Sign Up to Dealert